Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Clofarabine and other novel agents in AML; interview with Alan Burnett at ASH 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 16.01.13
Views: 22499

Prof Alan Burnett - Head of Haematology Department of Medical Genetics, Cardiff, Wales

Professor Alan Burnett, Head of Haematology Department of Medical Genetics, Cardiff, Wales, talks to ecancer.TV about the nucleoside analogue, clofarabine, in acute myeloid leukaemia (AML).  He outlines the interesting history, the early promise of the drug in older patients and the original clinical studies in three different patient groups.  Professor Burnett then discusses the best combination with clofarabine, including ara-C.  He goes on to note other compounds being studied in AML, such as agents that target FLT3 mutations in relapsed disease, eg, AC220, and outlines the pros and cons.


Other aspects touched on that are yet to be tested in the randomised setting include the benefit of prognostic mutations.  Also, Professor Burnett discusses the techniques being developed for minimal residual disease assessment and the potential value of these.


Finally, Professor Burnett updates viewers on advances in the management of elderly patients with AML.


This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation